| Chemotherapy-Minimized Blank Microsphere Transarterial Embolization (BMS-TACE) Plus Low-Dose Lenvatinib, Iparomlimab and Tuvonralimab, and SBRT in Hepatocellular Carcinoma With Macrovascular Tumor Thrombus | Lenvatinib | Phase 2 | Recruiting | Sun Yat-sen University | Nov 20, 2026 |
| Yangyin Qingfei Decoction for Radiation Pneumonitis Prevention | Nintedanib | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhejiang Chinese Medical University | Nov 17, 2026 |
| Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma. | Lenvatinib | Phase 2 | Recruiting | Kidney Cancer Research Bureau | Nov 16, 2026 |
| A Single-Arm, Exploratory, Phase II Study of Iparomlimab and Tuvonralimab Combined With Local Therapy as First-Line Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | Lenvatinib | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | Nov 16, 2026 |
| A Trial Evaluating Two Imetelstat Doses in Participants With Lower Risk Myelodysplastic Syndrome (MDS) | Motesanib | Phase 4 | Not yet recruiting | Geron Corporation | Nov 16, 2026 |
| Efficacy and Safety Exploration of Short Course Radiotherapy Followed by Surufatinib and Toripalimab in Neoadjuvant Treatment of Locally Advanced Rectal Cancer | Surufatinib | Phase 2 / Phase 3 | Recruiting | The First Hospital of Jilin University | Nov 13, 2026 |
| Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors | Lenvatinib | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | Nov 12, 2026 |
| QL1706 and Lenvatinib Combined With FOLFOX Systemic Chemotherapy as Second-line Treatment in Advanced Hepatocellular Carcinoma Patients | Lenvatinib | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Nov 12, 2026 |
| A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary Fibrosis | Nintedanib | Phase 2 | Not yet recruiting | CSPC-NBP Pharmaceutical Co., Ltd. | Nov 12, 2026 |
| Predictive Factors of Long-term Survivor (LTS) of Patients With Recurrent or Metastatic, Radio-iodine Resistant Differentiated Thyroid Cancer (RRDTC) After Lenvatinib: a Multicenter Study | Lenvatinib | — | Not yet recruiting | IRCCS San Raffaele | Nov 10, 2026 |
| Lenvatinib And Stereotactic radiothErapy With pembRolizumab in Metastatic Kidney Cancer Patients | Lenvatinib | Phase 2 | Recruiting | Kidney Cancer Research Bureau | Nov 10, 2026 |
| Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma | Lenvatinib | Phase 2 | Not yet recruiting | Sun Yat-sen University | Nov 6, 2026 |
| Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma | Fruquintinib | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Nov 5, 2026 |
| GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer | Fruquintinib | Phase 3 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | Nov 3, 2026 |
| Liver Transplantation Versus Conventional Medical Therapy for Low-Grade GEP-NET With Liver Metastases | Sunitinib | — | Enrolling by invitation | Chiyi Chen | Nov 3, 2026 |
| Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT | Motesanib | Phase 1 | Not yet recruiting | University of Wisconsin, Madison | Nov 2, 2026 |
| Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy Combined With Penpulimab and Fruquintinib for Advanced Colorectal Cancer | Fruquintinib | Phase 2 | Not yet recruiting | West China Hospital | Oct 29, 2026 |
| A Phase III Randomized Controlled Trial of Serplulimab Plus Fruquintinib as Adjuvant Therapy for High-Risk Non-Clear Cell Renal Cell Carcinoma | Fruquintinib | Phase 3 | Not yet recruiting | Sun Yat-sen University | Oct 29, 2026 |
| Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later Treatment | Fruquintinib | Phase 2 | Recruiting | Renmin Hospital of Wuhan University | Oct 26, 2026 |
| SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer | Fruquintinib | Phase 2 | Recruiting | Ruijin Hospital | Oct 22, 2026 |
| Fruquintinib Combined With Capecitabine as Adjuvant Extended Therapy After R0 Resection and Perioperative Chemotherapy in Patients With Liver-Only Metastatic Colorectal Cancer | Fruquintinib | Phase 3 | Not yet recruiting | West China Hospital | Oct 21, 2026 |
| Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell Carcinoma | Sunitinib | Phase 3 | Active, not recruiting | Sun Yat-sen University | Oct 20, 2026 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors | Regorafenib | Phase 1 / Phase 2 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | Oct 5, 2026 |
| First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in Spain | Axitinib, Pazopanib, Sunitinib, Tivozanib | — | Active, not recruiting | Bristol-Myers Squibb | Oct 1, 2026 |
| Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma | Sorafenib | Phase 3 | Recruiting | BeOne Medicines | Sep 23, 2026 |
| Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC | Surufatinib | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | Sep 22, 2026 |
| MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas | Axitinib | Phase 2 | Not yet recruiting | Fudan University | Sep 14, 2026 |
| A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric Cancer | Fruquintinib | Phase 2 | Not yet recruiting | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | Sep 14, 2026 |
| Real-world Insight Into Systemic Therapies for HCC: Single-center Study | Sorafenib | — | Recruiting | Mansoura University | Sep 10, 2026 |
| Molecularly Tailored Therapy in Advanced Pancreatic Cancer | Axitinib | Phase 2 | Not yet recruiting | Herlev Hospital | Sep 3, 2026 |
| Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma | Sorafenib | Phase 2 | Recruiting | Anna Raciborska | Aug 26, 2026 |
| Real-World Study of the Safety and Efficacy of Surufatinib in the Treatment of Neuroendocrine Tumors | Surufatinib | — | Not yet recruiting | Yefeng | Aug 21, 2026 |
| TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell Carcinoma | Axitinib | Phase 2 | Not yet recruiting | Fudan University | Aug 20, 2026 |
| Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer | Regorafenib | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | Aug 14, 2026 |
| A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer | Regorafenib | Phase 1 / Phase 2 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | Aug 6, 2026 |
| SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma | Axitinib | Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | Aug 4, 2026 |
| A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan | Regorafenib | Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | Jul 28, 2026 |
| IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer | Regorafenib | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | Jul 23, 2026 |
| Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis | Nintedanib | — | Not yet recruiting | Bristol-Myers Squibb | Jul 23, 2026 |
| DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML | Sorafenib | Phase 3 | Recruiting | The Second Affiliated Hospital of Kunming Medical University | Jul 20, 2026 |
| Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome | Regorafenib | Phase 2 | Not yet recruiting | Xiang-Qian | Jul 9, 2026 |
| A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib | Regorafenib, Sunitinib | Phase 2 | Recruiting | GlaxoSmithKline | Jul 8, 2026 |
| Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis | Nintedanib | Phase 2 | Recruiting | Mannkind Corporation | Jul 1, 2026 |
| An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer | Sunitinib | Phase 2 | Recruiting | Bai-Rong Xia | Jun 25, 2026 |
| A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold Regions | Sorafenib | — | Active, not recruiting | Harbin Medical University | Jun 12, 2026 |
| PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC | Axitinib | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Jun 5, 2026 |
| A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension | Nintedanib | — | Not yet recruiting | Cosmos Rx, Inc | May 29, 2026 |
| Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC | Surufatinib | Phase 2 | Recruiting | Sun Yat-sen University | May 27, 2026 |
| Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degeneration | Axitinib | Phase 2 | Not yet recruiting | SCAI Therapeutics | May 26, 2026 |
| Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Nintedanib | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | May 13, 2026 |
| Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML | Sorafenib | — | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | May 7, 2026 |
| Clinical Study of Novel Therapeutic Vaccine for Advanced Solid Tumors | Regorafenib | Phase 1 | Recruiting | West China Hospital | May 5, 2026 |
| SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin | Sorafenib | Phase 2 | Recruiting | National Taiwan University Hospital | May 1, 2026 |
| Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms | Motesanib | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | Apr 24, 2026 |
| Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study | Surufatinib | — | Active, not recruiting | West China Hospital | Apr 16, 2026 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis | Nintedanib | Phase 3 | Not yet recruiting | Haisco Pharmaceutical Group Co., Ltd. | Apr 9, 2026 |
| Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study | Axitinib | Phase 3 | Recruiting | Ocular Therapeutix, Inc. | Apr 7, 2026 |
| Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria | Surufatinib | Phase 2 / Phase 3 | Recruiting | The First Hospital of Jilin University | Apr 1, 2026 |
| Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD | Nintedanib | — | Recruiting | University of Patras | Mar 24, 2026 |
| A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma | Sunitinib | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | Mar 17, 2026 |
| Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer | Surufatinib | Phase 2 | Not yet recruiting | Sun Yat-sen University | Mar 13, 2026 |
| MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib | Sorafenib | Phase 3 | Recruiting | The First Affiliated Hospital of Soochow University | Mar 11, 2026 |
| A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas | Pazopanib | Phase 1 | Recruiting | M.D. Anderson Cancer Center | Mar 3, 2026 |
| Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer | Surufatinib | Phase 3 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | Feb 27, 2026 |
| Imetelstat Combinations in Relapsed AML | Motesanib | Phase 1 | Recruiting | Douglas Tremblay | Jan 6, 2026 |
| A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy | Sunitinib | Phase 3 | Recruiting | GlaxoSmithKline | Oct 21, 2025 |
| A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI | Sunitinib | Phase 3 | Not yet recruiting | Peking University Cancer Hospital & Institute | Sep 10, 2025 |
| A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma | Pazopanib | Phase 2 | Recruiting | Imbioray (Hangzhou) Biomedicine Co., Ltd. | Jul 25, 2025 |
| Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1) | Pazopanib | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University Second Hospital | Mar 26, 2025 |
| Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents | Pazopanib | Phase 2 | Recruiting | Shandong Cancer Hospital and Institute | Feb 10, 2025 |
| Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion | Pazopanib | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | Dec 18, 2024 |
| Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study) | Pazopanib | Phase 3 | Recruiting | Sun Yat-sen University | Dec 10, 2024 |
| Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer | Tivozanib | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | Oct 28, 2024 |
| Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer | Vandetanib | Phase 2 | Recruiting | West China Hospital | Jul 1, 2024 |
| A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) | Pazopanib | Phase 3 | Recruiting | Intensity Therapeutics, Inc. | Feb 16, 2024 |
| A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy | Motesanib | Phase 1 | Recruiting | Children's Oncology Group | Feb 8, 2024 |
| Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma | Tivozanib | Phase 2 | Active, not recruiting | M.D. Anderson Cancer Center | Sep 26, 2023 |
| Multicenter Trial of ESK981 in Patients With Select Solid Tumors | CEP-11981 | Phase 2 | Active, not recruiting | University of Michigan Rogel Cancer Center | Aug 14, 2023 |
| Drug Screening Using Novel IMD in Renal Cell Carcinoma | Tivozanib | Phase 1 | Recruiting | Oliver Jonas | Jan 26, 2023 |
| A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors | Tivozanib | Phase 1 | Recruiting | Arcus Biosciences, Inc. | Sep 10, 2022 |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis | Motesanib | Phase 1 | Active, not recruiting | Geron Corporation | May 12, 2022 |
| Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | Tivozanib | Phase 1 / Phase 2 | Recruiting | University of Florida | Aug 11, 2021 |
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | Cediranib | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | Feb 5, 2021 |
| TDM for Optimized Outcome in Patients With mRCC. | Tivozanib | — | Recruiting | Niels Fristrup | Dec 9, 2020 |
| Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers | Tivozanib | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | Nov 27, 2020 |
| A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment | Motesanib | Phase 3 | Active, not recruiting | Geron Corporation | Oct 6, 2020 |
| A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer | Cediranib | Phase 2 | Active, not recruiting | The Clatterbridge Cancer Centre NHS Foundation Trust | Jul 27, 2020 |
| A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer | Vandetanib | Phase 3 | Active, not recruiting | Loxo Oncology, Inc. | Dec 26, 2019 |
| Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer | Cediranib | Phase 2 | Recruiting | M.D. Anderson Cancer Center | Sep 16, 2019 |
| Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors | Cediranib | Phase 2 | Active, not recruiting | University Health Network, Toronto | Feb 22, 2019 |
| WIRE - Novel Treatments in Renal Cell Cancer | Cediranib | Phase 2 | Recruiting | CCTU- Cancer Theme | Nov 14, 2018 |
| Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone | Cediranib | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | Sep 7, 2018 |
| Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy | Cediranib | Phase 2 | Active, not recruiting | AstraZeneca | Nov 7, 2017 |
| Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma | Cediranib | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | Nov 28, 2016 |
| Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | Motesanib | Phase 2 / Phase 3 | Active, not recruiting | Geron Corporation | Nov 6, 2015 |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer | Vandetanib | Phase 2 | Active, not recruiting | UNICANCER | Nov 24, 2014 |